--- title: "Imunon (IMNN) news: delisting, going concern and offering" url: "https://aibio.space/companies/imunon/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IMNN delisting, going concern and offering news: Imunon gets Nasdaq Hearing Panel exception after delisting determination. Imunon, Inc." --- IMNN Imunon, Inc. NASDAQ · United States # Imunon (IMNN) news IMNN delisting, going concern and offering news Financings · 2026-10-27 ## [Imunon files for share offering with 350% warrant coverage in four tranches](https://aibio.space/news/imunon-files-share-offering-350-percent-warrant-coverage-four-tranches/) Imunon's preliminary prospectus covers up to 20,000,000 shares, sold with warrants that could cover up to 70,000,000 more. The auditor's opinion on 2025 results includes substantial doubt about the company's ability to continue as a going concern. ## Latest Imunon news 1. 2026-09-29 Financings [Imunon agrees to swap $1,200,000 of Streeterville note for Series B preferred](https://aibio.space/news/imunon-agrees-swap-1-200-000-streeterville-note-series-b-preferred/) Imunon will exchange $1,200,000 of a Streeterville note for 120 Series B preferred shares that cannot convert into common stock but carry an 8% return. Cash and cash equivalents were $6.9 million at June 30, 2026. 2. 2026-06-04 Debt Financing [IMUNON to raise $10 million through preferred stock and secured notes](https://aibio.space/news/imunon-raise-10-million-through-preferred-stock-secured-notes/) IMUNON has sold $10 million of preferred stock and two secured notes to Streeterville Capital, with half placed in a collateral account, to fund its Phase 3 OVATION 3 trial. The company used $13.9 million in operations in 2025. 3. 2025-08-28 Listings [Imunon regains compliance with Nasdaq minimum bid price requirement](https://aibio.space/news/imunon-regains-compliance-nasdaq-minimum-bid-price-requirement/) Imunon (Nasdaq: IMNN) says the Nasdaq Hearings Panel notified it on August 27, 2025 that it meets the $1.00 minimum closing bid price. The stock will continue trading on the Nasdaq Capital Market. 4. 2025-08-28 Listings [Imunon regains Nasdaq minimum bid price compliance after hearings panel confirmation](https://aibio.space/news/imunon-regains-nasdaq-minimum-bid-price-compliance-after-hearings/) The Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent 15% stock dividend. 5. 2025-07-14 Listings [Imunon gets Nasdaq Hearing Panel exception after delisting determination](https://aibio.space/news/imunon-gets-nasdaq-hearing-panel-exception-after-delisting/) The panel granted the exception on July 11, 2025, so Imunon can regain compliance with the $1.00 minimum bid price and the stockholders' equity requirement. Stockholders also approved 2,000,000 more plan shares, bringing the plan's limit to 3,970,000. ## Imunon at a glance - **Ticker**: IMNN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $6.9 million ### Related companies - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) NASDAQ: IPSC - [Taysha Gene Therapies](https://aibio.space/companies/taysha-gene-therapies/) NASDAQ: TSHA - [OS Therapies](https://aibio.space/companies/os-therapies/) AMEX: OSTX - [MiNK Therapeutics](https://aibio.space/companies/mink-therapeutics/) NASDAQ: INKT - [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) NASDAQ: GENB - [Apnimed](https://aibio.space/companies/apnimed/) NASDAQ: APMD - [CorMedix](https://aibio.space/companies/cormedix/) NASDAQ: CRMD - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) NASDAQ: KRSA ### Also on NASDAQ - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) DMAC - [PTC Therapeutics](https://aibio.space/companies/ptc-therapeutics/) PTCT - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) BDTX - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) KLRS - [Viatris](https://aibio.space/companies/viatris/) VTRS ## What Imunon does Imunon, Inc. is a clinical-stage biotechnology company developing treatments that harness the body's natural mechanisms. It develops non-viral DNA technology across two modalities. TheraPlas codes for proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. PlaCCine codes for viral antigens that may support vaccines for infectious diseases. The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. The company says IMNN-001 has completed multiple clinical trials, including one Phase II trial (OVATION 2), and is currently conducting a Phase 3 trial (OVATION 3). Imunon also reports that it has completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101. Its technology uses synthetic non-viral carriers to deliver plasmid DNA and mRNA, and the delivery system is designed to protect the DNA or mRNA from degradation. The company says it will advance these modalities directly or through partnership. | Product or program | What it is | Stage | |---|---|---| | IMNN-001 | DNA-based immunotherapy for localized treatment of advanced ovarian cancer | Phase 3 (OVATION 3) ongoing | | IMNN-101 | COVID-19 booster vaccine | first-in-human study dosing completed | | TheraPlas | Non-viral DNA modality coding proteins and cytokines for solid tumors | | | PlaCCine | Non-viral DNA modality coding viral antigens for infectious disease vaccines | | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/form10-k.htm). ## Imunon annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$7.8 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/) | [$11.6 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/) | | Net income (loss) | [-$14.5 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/) | [-$18.6 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/) | | Cash from operations | [-$13.9 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/) | [-$18.9 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/) | | Cash and equivalents | [$8.8 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226036991/) | [$5.9 million](https://www.sec.gov/Archives/edgar/data/749647/000149315226013850/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Imunon Was Imunon delisted? Our latest story on this, dated Jul 14, 2025: "Imunon gets Nasdaq Hearing Panel exception after delisting determination". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/imunon-gets-nasdaq-hearing-panel-exception-after-delisting/). Has Imunon issued a going-concern warning? Our latest story on this, dated Oct 27, 2026: "Imunon files for share offering with 350% warrant coverage in four tranches". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/imunon-files-share-offering-350-percent-warrant-coverage-four-tranches/). Has Imunon raised money recently? Our latest story on this, dated Oct 27, 2026: "Imunon files for share offering with 350% warrant coverage in four tranches". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/imunon-files-share-offering-350-percent-warrant-coverage-four-tranches/). What is the ticker symbol of Imunon? Imunon, Inc. trades under the ticker IMNN on NASDAQ. Where is Imunon listed? Imunon, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:CBO0; LSX:A41CNR. What is the SEC CIK of Imunon? The SEC Central Index Key (CIK) for Imunon, Inc. is 749647. Its filings are on SEC EDGAR. How many shares does Imunon have outstanding? 5,611,403 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Imunon listed under? Our directory records Imunon, Inc. under United States. What does Imunon do? Our directory classifies Imunon, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Imunon? The ISIN recorded for Imunon, Inc. is US15117N7012. Does aibio.space cover Imunon? aibio.space lists Imunon, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Imunon incorporated? SEC records list its state or country of incorporation as DE. What does Imunon develop? Imunon, Inc. is a clinical-stage biotechnology company developing treatments that harness the body's natural mechanisms. It develops non-viral DNA technology across two modalities. What is IMNN-001 from Imunon? IMNN-001: DNA-based immunotherapy for localized treatment of advanced ovarian cancer Stage: Phase 3 (OVATION 3) ongoing. What is IMNN-101 from Imunon? IMNN-101: COVID-19 booster vaccine Stage: first-in-human study dosing completed. ## Investor discussion: Imunon Members talk about Imunon (IMNN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Imunon, newest first. Each line links the filing it comes from. 1. 2026-10-27 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315226048630/forms-1.htm) 2. 2026-09-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315226044792/form8-k.htm) 3. 2026-06-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/ex99-1.htm) 4. 2026-03-23 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315226012161/form424b5.htm) 5. 2025-12-31 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315225029711/ex99-1.htm) 6. 2025-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/ex99-1.htm) 7. 2025-07-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225020652/ex99-1.htm) 8. 2025-07-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225020519/form424b5.htm) 9. 2025-07-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225019541/form8-k.htm) 10. 2025-07-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225018797/form8-k.htm) 11. 2025-06-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225014279/form8-k.htm) 12. 2025-06-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225014324/formdef14a.htm) 13. 2025-05-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225013051/form8-k.htm) 14. 2025-05-30 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225013068/formpre14a.htm) 15. 2025-05-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225012395/ex99-1.htm) 16. 2025-05-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225011601/form8-k.htm) 17. 2025-05-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225009775/form8-k.htm) 18. 2025-04-04 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/749647/000164117225002783/forms-1.htm) 19. 2025-02-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/ex99-1.htm) 20. 2024-11-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/749647/000149315224048008/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IMNN on TradingView](https://www.tradingview.com/symbols/NASDAQ-IMNN/). ## SEC filings and registration - **SEC name**: Imunon, Inc. - **CIK**: 749647 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: IMNN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 997 LENOX DRIVE, LAWRENCEVILLE, NJ, 08648 - **Phone**: (609) 896-9100 - **Shares outstanding**: 5,611,403 as of 2026-08-10 (10-Q filed 2026-08-11) - **Former names**: CELSION CORP; Celsion CORP; CHEUNG LABORATORIES INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/749647/000149315226047850/form8-k.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/749647/000149315226044792/form8-k.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/749647/000149315226037170/form8-k.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/749647/000149315226036991/form10-q.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/form8-k.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/749647/000149315226031292/form8-k.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/749647/000149315226028937/form8-k.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/form8-k.htm) filed 2026-06-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000749647), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Imunon, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMNN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Imunon, Inc. - **Ticker**: IMNN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US15117N7012 - **Other listed symbols**: GETTEX:CBO0; LSX:A41CNR - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IMNN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/imunon/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Imunon (IMNN) news: delisting, going concern and offering", 2026-10-31, https://aibio.space/companies/imunon/